Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice

Diabetologia

Volumn 58, Issue 9, 2015, Pages 2144-2153

  Pathak, Varun ^a   Vasu, Srividya ^a   Gault, Victor A ^a   Flatt, Peter R ^a   Irwin, Nigel ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

db db mice; Diabetes; GIP; GLP 1; Glucose homeostasis; Insulin secretion; Obesity

Indexed keywords

CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE[6-30]C TERMINAL EXTENSION K 40 [PAL]; GLUCOSE; HORMONE INHIBITOR; INSULIN; LIRAGLUTIDE; UNCLASSIFIED DRUG; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; INCRETIN;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CELL STIMULATION; CONTROLLED STUDY; DIABETES CONTROL; DOSE RESPONSE; DRUG EFFICACY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; LIGHT DARK CYCLE; LIPID STORAGE; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX; ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CYTOLOGY; DRUG ADMINISTRATION; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HAMSTER; HOMEOSTASIS; HUMAN; MASS SPECTROMETRY; METABOLISM; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PROTEIN TERTIARY STRUCTURE; SECRETION (PROCESS);

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CRICETINAE; CYCLIC AMP; DIABETES MELLITUS, EXPERIMENTAL; DRUG ADMINISTRATION SCHEDULE; FATTY ACIDS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HOMEOSTASIS; HUMANS; INCRETINS; INFUSIONS, PARENTERAL; INSULIN; INSULIN-SECRETING CELLS; LIRAGLUTIDE; MALE; MICE; MICE, INBRED C57BL; PROTEIN STRUCTURE, TERTIARY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84938750467     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3653-1     Document Type: Article

References (32)

1. Brown RJ, Rother KI (2008) Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data. Pediatr Diabetes 9:14–22
2. Hansen JB, Arkhammar PO, Bodvarsdottir TB, Wahl P (2004) Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders. Curr Med Chem 11:1595–1615
3. King A (2013) Integrating advances in insulin into clinical practice: advances in insulin formulations. J Fam Pract 62:S9–S17
4. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY (2005) Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90:501–506
5. Irwin N, Flatt PR (2009) Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia 52:1724–1731
6. Nasteska D, Harada N, Suzuki K et al (2014) Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high fat diet condition. Diabetes 63:2332–2343
7. de Toro-Martín J, Fernández-Millán E, Lizárraga-Mollinedo E et al (2014) Predominant role of GIP in the development of a metabolic syndrome-like phenotype in female Wistar rats submitted to forced catch-up growth. Endocrinology 155:3769–3780
8. Drucker DJ (2007) The role of gut hormones in glucose homeostasis. J Clin Invest 117:24–32
9. Skak K, Gotfredsen CF, Lundsgaard D, Hansen JB, Sturis J, Markholst H (2004) Improved beta-cell survival and reduced insulitis in a type 1 diabetic rat model after treatment with a beta-cell-selective K(ATP) channel opener. Diabetes 53:1089–1095
10. Gault VA, Irwin N, Green BD et al (2005) Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54:2436–2446
11. McClean PL, Irwin N, Hunter K, Gault VA, Flatt PR (2008) (Pro3)GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy. Br J Pharmacol 155:690–701
12. Nakamura T, Tanimoto H, Mizuno Y, Tsubamoto Y, Noda H (2012) Biological and functional characteristics of a novel low-molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL-14959, in vitro and in vivo. Diabetes Obes Metab 14:511–517
13. Pathak V, Gault VA, Flatt PR, Irwin N (2014) Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice. Mol Cell Endocrinol 401:120–129
14. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131–2157
15. Gelling RW, Coy DH, Pederson RA et al (1997) GIP(6-30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42 action in vitro. Regul Pept 69:151–154
16. Coleman DL, Hummel KP (1967) Studies with the mutation, diabetes, in the mouse. Diabetologia 3:238–248
17. McClenaghan NH, Barnett CR, O’Harte FP, Flatt PR (1996) Mechanisms of amino acid-induced insulin secretion from the glucose-responsive BRIN-BD11 pancreatic B cell line. J Endocrinol 151:349–357
18. Flatt PR, Bailey CJ (1981) Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20:573–577
19. Irwin N, Clarke GC, Green BD et al (2006) Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide. Biochem Pharmacol 72:719–728
20. Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR (2007) Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diet. Diabetologia 50:1752–1762
21. Simonsen L, Holst JJ, Madsen K, Deacon CF (2013) The C-terminal extension of exendin 4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs. Regul Pept 10:17–21
22. Tartarkiewicz K, Hargrove DM, Jodka CM et al (2014) A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents. Diabetes Obes Metab 16:75–85
23. Albrecht U, Oster H (2001) The circadian clock and behavior. Behav Brain Res 125:89–91
24. Alemzadeh R, Tushaus KM (2004) Modulation of adipoinsular axis in prediabetic zucker diabetic fatty rats by diazoxide. Endocrinology 145:5476–5484
25. Ritzel RA, Hansen JB, Veldhuis JD, Butler PC (2004) Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose. J Clin Endocrinol Metab 89:795–805
26. Kim WH, Lee JW, Suh YH et al (2005) Exposure to chronic high glucose induces β-cell apoptosis through decreased interaction of glucokinase with mitochondria: downregulation of glucokinase in pancreatic β-cells. Diabetes 54:2602–2611
27. Alemzadeh R, Holshouser S, Massey P, Koontz J (2002) Chronic suppression of insulin by diazoxide alters the activities of key enzymes regulating hepatic gluconeogenesis in Zucker rats. Eur J Endocrinol 146:871–879
28. Karpe F, Dickmann JR, Frayn KN (2011) Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 60:2441–2449
29. Bhat VK, Kerr BD, Vasu S, Flatt PR, Gault VA (2013) A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice. Diabetologia 56:1417–1424
30. Dalbøge LS, Almholt DL, Neerup TS, Vrang N, Jelsing J, Fosgerau K (2014) The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases β-cell mass without affecting islet number in db/db mice. J Pharmacol Exp Ther 350:353–360
31. Finan B, Yang B, Ottaway N et al (2015) A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21:27–36
32. Gault VA, Bhat VK, Irwin N, Flatt PR (2013) A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice. J Biol Chem 288:35581–35591